T6200
Thrombin from bovine plasma
lyophilized powder, 40-300 NIH units/mg protein (biuret)
Synonym(s):
Factor IIa
form
lyophilized powder
specific activity
40-300 NIH units/mg protein (biuret)
composition
Protein, 40-60%
UniProt accession no.
storage temp.
−20°C
Gene Information
cow ... F2(280685)
Looking for similar products? Visit Product Comparison Guide
General description
Thrombin is the final coagulation protease in regard to hemostasis, promoting both procoagulant and anticoagulant effects. Lyophilized powder containing sucrose, sodium chloride and Tris.
Application
Thrombin is used for site specific cleavage of recombinant fusion proteins containing an accessible thrombin recognition site for removal of affinity tags. Thrombin has been used in a study to assess characterization of platelet dysfunction after trauma.
Biochem/physiol Actions
Serine protease that selectively cleaves Arg-Gly bonds in fibrinogen to form fibrin and fibrinopeptides A and B.
Physical form
Lyophilized powder containing sodium chloride and Tris-HCl, pH 7.0
Preparation Note
Prepared using bovine lung thromboplastin for conversion to the active form.
Analysis Note
Activity is expressed in NIH units obtained by direct comparison to a NIH Thrombin Reference Standard, Lot K.
The NIH assay procedure uses 0.2 mL of diluted plasma (1:1 with saline) as a substrate and 0.1 mL of thrombin sample (stabilized in a 1% buffered albumin solution) based on a modification of the method of Biggs. Only clotting times in the range of 15-25 seconds are used for determining thrombin concentrations.
Other Notes
View more information on thrombin at www.sigma-aldrich.com/enzymeexplorer.
Signal Word
Danger
Hazard Statements
Precautionary Statements
Hazard Classifications
Eye Irrit. 2 - Resp. Sens. 1 - Skin Irrit. 2 - STOT SE 3
Target Organs
Respiratory system
Storage Class Code
11 - Combustible Solids
WGK
WGK 2
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Matthew E Kutcher et al.
The journal of trauma and acute care surgery, 73(1), 13-19 (2012-06-30)
The increased morbidity and mortality associated with coagulopathy and thrombocytopenia after trauma are well described. However, few studies have assessed platelet function after injury. Blood samples were prospectively collected from 101 patients with critical injury and trauma on arrival to
Dabigatran: a nephrological way out.
Patricio A Pazmiño
The American journal of medicine, 126(4), e21-e21 (2013-03-20)
Inhibitory effect of apixaban compared with rivaroxaban and dabigatran on thrombin generation assay.
Pancras C Wong et al.
Hospital practice (1995), 41(1), 19-25 (2013-03-08)
The effect of the oral direct activated factor X (factor Xa) inhibitor apixaban on tissue factor-induced thrombin generation in human plasma was investigated in vitro using the calibrated automated thrombogram (CAT) method and compared with the oral direct factor Xa
Marc P Bonaca et al.
Circulation, 127(14), 1522-1529 (2013-03-19)
Vorapaxar is a novel antagonist of protease-activated receptor-1, the primary receptor for thrombin on human platelets that is also present on vascular endothelium and smooth muscle. Patients with peripheral artery disease are at risk of systemic atherothrombotic events, as well
Response.
Sarah T Garber et al.
Journal of neurosurgery, 118(2), 483-483 (2013-03-16)
Related Content
Instructions
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service